Cyberknife MarketGlobal CyberKnife Market Size, Share and Report Analysis By Product (Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy), Indication (Benign Tumors, Malignant Tumors, Vascular Lesions, Others), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035

Market Overview

Global CyberKnife Market size is expected to be worth around US$ 794.0 Million by 2035 from US$ 456.1 Million in 2025, growing at a CAGR of 5.7% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 48.7% share with a revenue of US$ 222.1 Million.

The CyberKnife market continues to gain momentum as healthcare providers increasingly adopt highly precise, image-guided radiosurgery systems for the treatment of complex tumors. Unlike conventional radiation therapy, the CyberKnife System uses robotic technology and real-time image guidance to deliver stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), enabling clinicians to treat tumors throughout the body while minimizing radiation exposure to surrounding healthy tissues.

The U.S. Food and Drug Administration (FDA) has cleared multiple generations of the CyberKnife System for stereotactic radiosurgery and precision radiotherapy, supporting its clinical use across a wide range of oncologic indications. The growing global cancer burden remains the primary factor supporting demand for advanced radiosurgery platforms.

According to the National Cancer Institute (NCI), radiation therapy is used in the treatment of more than half of all people diagnosed with cancer during the course of their disease, making it one of the most widely utilized cancer treatment modalities worldwide. Radiation therapy damages the DNA of cancer cells, preventing them from growing and dividing, while technological advances continue to improve treatment precision and patient outcomes.

Clinical adoption is also being driven by the increasing preference for non-invasive treatment options that reduce hospitalization and recovery time. CyberKnife technology provides sub-millimeter targeting accuracy through continuous image guidance and robotic beam delivery, allowing treatment of tumors that move with respiration and lesions located near critical organs.

These capabilities have expanded its application in brain, spine, lung, liver, pancreas, and prostate cancers. The National Cancer Institute further recognizes stereotactic radiosurgery as a highly precise form of external radiation therapy designed to accurately deliver concentrated radiation doses to tumors while limiting damage to nearby healthy tissue.

Healthcare systems are also investing in advanced radiation oncology infrastructure to improve access to precision cancer care. Continuous technological innovation, greater clinical evidence supporting hypofractionated treatment approaches, and increasing awareness of minimally invasive cancer therapies are expected to support long-term demand for CyberKnife systems across hospitals and specialized cancer centers worldwide.

Key Takeaways

• Market Size : Global CyberKnife Market size is expected to be worth around US$ 794.0 Million by 2035 from US$ 456.1 Million in 2025.
• Market Share : The market is growing at a CAGR of 5.7% during the forecast period from 2026 to 2035.
• Product Type Analysis : The Stereotactic Radiosurgery (SRS) segment dominated the CyberKnife market in 2025, accounting for 56.8% of the total market share.
• Indication Analysis : The Malignant Tumors segment led the CyberKnife market in 2025, capturing 72.5% of the total market share.
• End User Analysis : Hospitals dominated the CyberKnife market in 2025, accounting for 62.1% of the total market share.
• Regional Analysis : In 2025, North America led the market, achieving over 48.7% share with a revenue of US$ 222.1 Million.

Product Type Analysis

The Stereotactic Radiosurgery (SRS) segment dominated the CyberKnife market in 2025, accounting for 56.8% of the total market share. SRS is widely used for treating brain tumors, brain metastases, arteriovenous malformations, and other neurological disorders with exceptional precision.

The CyberKnife System is specifically designed to deliver high-dose radiation with sub-millimeter accuracy while avoiding damage to surrounding healthy tissues, making it a preferred non-invasive alternative to conventional surgery for many intracranial conditions.

Increasing clinical evidence supporting shorter treatment times, improved patient outcomes, and reduced recovery periods continues to drive adoption of SRS. The growing number of cancer centers offering advanced stereotactic treatments and continuous technological improvements in robotic image guidance further strengthen this segment. The National Cancer Institute (NCI) recognizes stereotactic radiosurgery as a highly precise external radiation therapy used primarily for brain tumors and certain neurological disorders.

The Stereotactic Body Radiation Therapy (SBRT) segment held the remaining 43.2% market share in 2025 and continues to expand rapidly. SBRT is increasingly utilized for tumors located outside the brain, including lung, liver, pancreas, prostate, and spine cancers.

The CyberKnife System enables real-time tumor tracking during patient movement, allowing highly accurate radiation delivery in only a few treatment sessions. Growing preference for minimally invasive cancer treatment, rising incidence of solid tumors, and increasing adoption of hypofractionated radiotherapy are expected to support steady growth of the SBRT segment.

Indication Analysis

The Malignant Tumors segment led the CyberKnife market in 2025, capturing 72.5% of the total market share. The high prevalence of cancers such as lung, prostate, liver, pancreatic, spine, and brain tumors has significantly increased the demand for precise robotic radiosurgery.

CyberKnife technology provides highly conformal radiation with real-time image guidance, making it suitable for treating tumors located near critical organs while minimizing damage to healthy tissues.

Increasing adoption of stereotactic radiotherapy as an alternative to invasive surgery, particularly among elderly or medically inoperable patients, continues to support segment growth. According to the National Cancer Institute, radiation therapy is used in the treatment of more than half of all cancer patients, highlighting its essential role in modern oncology.

The Benign Tumors segment represents the second-largest share, supported by growing use of CyberKnife for conditions such as meningiomas, vestibular schwannomas, and pituitary adenomas where surgery may carry higher risks.

The Vascular Lesions segment also contributes steadily, particularly for treating arteriovenous malformations (AVMs) through highly targeted radiosurgery. The Others category includes selected functional neurological disorders and rare clinical indications, which continue to expand as clinical research broadens the applications of stereotactic radiosurgery and stereotactic body radiation therapy.

End User Analysis

Hospitals dominated the CyberKnife market in 2025, accounting for 62.1% of the total market share. Large hospitals remain the primary end users because they possess the infrastructure, multidisciplinary oncology teams, and financial resources required to install and operate advanced robotic radiosurgery systems.

These institutions also manage a high volume of complex cancer cases requiring precision radiation therapy. Growing investments in comprehensive cancer centers, increasing availability of image-guided radiotherapy, and rising demand for minimally invasive cancer treatments continue to strengthen hospital adoption. Hospitals also participate actively in clinical research, helping expand the clinical applications of CyberKnife technology for both intracranial and extracranial tumors.

Specialty Clinics represent the second-largest segment, driven by increasing establishment of dedicated oncology and radiosurgery centers offering outpatient stereotactic treatments with shorter treatment schedules. These facilities provide specialized expertise while improving patient convenience.

Ambulatory Surgical Centers (ASCs) are gradually adopting advanced radiation technologies for selected outpatient procedures as healthcare systems shift toward cost-effective care models. The Other End-Users segment includes academic medical institutions, research hospitals, and government cancer centers that utilize CyberKnife systems for clinical studies, physician training, and specialized cancer treatment programs, contributing to the continued expansion of precision radiation therapy worldwide.

Market Segmentations

Product

• Stereotactic Radiosurgery
• Stereotactic Body Radiation Therapy

Indication

• Benign Tumors
• Malignant Tumors
• Vascular Lesions
• Others

End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Other End-Users

Driver

Rising oncology case load and survivorship intensity
Global cancer demand is the most durable volume driver for CyberKnife because it expands the addressable pool for high precision radiotherapy in brain, prostate, lung, spine, liver, and oligometastatic settings.

WHO reported about 20 million new cancer cases in 2022 and projects more than 35 million by 2050, a 77 % increase, while 53.5 million people were living within five years of a cancer diagnosis, which means more patients are surviving long enough to need localized retreatment, metastasis control, or toxicity sparing interventions that favor stereotactic precision.

WHO also states that treatment typically includes surgery, radiotherapy, and or systemic therapy, and a 2024 global radiotherapy standards paper estimates roughly 50 % of cancer patients need radiotherapy at some point in treatment, reinforcing the structural demand base for advanced radiosurgery capacity.

In practice, this demand disproportionately benefits tertiary centers that can monetize high acuity case mix through premium planning, image guidance, and motion management workflows; that is why the strongest commercial pull remains in North America, Western Europe, Japan, South Korea, and increasingly large Indian and Gulf cancer hubs where patient throughput and complex case referrals are rising.

Challenge

Vendor concentration, service fragility and critical component exposure
The CyberKnife market sits within a concentrated vendor and service ecosystem, making it vulnerable to disruptions in manufacturing capacity, field service availability, and key components such as robotic joints, X ray tubes, multileaf collimators, and computing boards, especially under global supply chain stress.

In radiotherapy and LINAC markets, installation backlogs can reach 9 to 18 months in peak periods, while downtime from component failures can reach 5 to 10 % of operating days in constrained settings where spare parts delivery takes weeks instead of the 24 to 72 hours targeted in service agreements.

For CyberKnife, even 3 to 5 extra downtime days per year can remove 30 to 60 fractions, or 5 to 10 % of stereotactic volume, directly affecting revenue and utilization. This fragility likely reduces potential market CAGR by about 0.6 % points, as delays and outages limit system uptime and installation flow.

Mitigation depends on dual sourcing of components, stronger regional parts networks, expanded third party service coverage, and predictive maintenance to reduce unplanned downtime by 30 to 50 %.

Restraints

Regulatory Complexity and HTA Delays Slowing CyberKnife Market Expansion
Advanced radiosurgery platforms such as CyberKnife face a complex regulatory and reimbursement environment that slows market expansion despite strong clinical evidence. In major markets, SRS technologies must meet strict device regulations, radiation safety requirements, and health technology assessment (HTA) processes across the US, Europe, Japan, and Australia, with varying standards and timelines.

This results in 12 to 24 month delays between regulatory clearance and reimbursement adoption in some markets, fragmented coverage that limits indications to tertiary centers, and repeated updates to clinical and economic evidence requirements.

Episode based payment models and tariff revisions add further uncertainty, often underrecognizing the cost intensity of robotic SRS compared to conventional radiotherapy. These factors delay hospital investment decisions, especially given long equipment lifecycles and reimbursement uncertainty. The overall effect is slower geographic rollout and a roughly 1 % point drag on global CyberKnife CAGR in the medium term.

Opportunity

Community oncology SBRT hub and spoke CyberKnife deployment networks
The main opportunity is expanding CyberKnife access from tertiary centers into community oncology networks through hub and spoke SBRT programs, targeting lung, prostate, spine, and liver cases still treated on LINACs despite evidence supporting stereotactic precision and lower toxicity. In the US, SBRT revenues are projected around 3.2 billion USD by 2034, with an estimated 15 to 20 % of volume potentially addressable by CyberKnife if workflow and capital barriers are reduced.

Hub and spoke models where one CyberKnife hub serves 3 to 5 community sites via shared planning and referral pathways can increase utilization from 250 to 350 cases per system per year to 500 to 600, improving asset productivity and margins.

However, adoption remains limited due to reliance on LINAC workflows, weak referral standardization, and reimbursement uncertainty. Wider deployment through partnerships and risk sharing models could add about 2.5 % points to sector CAGR through 2030.

Regional Analysis

In 2025, North America dominated the CyberKnife market, accounting for 48.7% of the global share and generating US$ 222.1 million in revenue. The region’s leadership is supported by advanced cancer treatment infrastructure, widespread adoption of stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), and strong investments in precision oncology.

The United States remains the largest contributor, benefiting from an extensive network of specialized cancer centers and continuous technological innovation. According to the U.S. National Cancer Institute (NCI), radiation therapy is used in the treatment of more than 50% of all cancer patients, reinforcing the growing need for highly accurate treatment platforms such as CyberKnife.

Europe represents the second-largest regional market due to its well-established healthcare systems, favorable reimbursement policies, and increasing adoption of image-guided radiotherapy across major countries. Government-backed cancer control initiatives continue to strengthen access to advanced radiation technologies.

The Asia-Pacific region is projected to witness the fastest growth, driven by rising cancer incidence, expanding healthcare infrastructure, and increasing investments in radiotherapy facilities across China, Japan, India, and South Korea. According to the International Atomic Energy Agency (IAEA), its DIRAC database tracks radiotherapy resources across more than 150 countries, highlighting continued expansion of global treatment capacity.

Meanwhile, Latin America and the Middle East & Africa are gradually improving access to advanced radiotherapy through government investments and support from international organizations such as the WHO and IAEA, which continue to promote equitable access to safe and effective cancer treatment worldwide.

Key Regions and Countries

North America

• The US
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Russia & CIS
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

Latin America

• Brazil
• Mexico
• Rest of Latin America

Key Player Analysis

The CyberKnife market is moderately consolidated, with a few global companies leading innovation in robotic radiosurgery, image-guided radiotherapy, and treatment planning software.

Accuray Incorporated remains the dominant player as the developer of the CyberKnife® System, offering the CyberKnife S7 and M6 platforms with AI-enabled motion tracking and sub-millimeter precision for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). The company has installed more than 300 systems worldwide and continues to expand its radiation oncology portfolio through advanced software and clinical collaborations.

Other major participants strengthen the competitive landscape through complementary technologies. Brainlab AG provides advanced treatment planning and contouring software that integrates with CyberKnife workflows to improve clinical efficiency.

Elekta AB is a leading supplier of linear accelerators and precision radiation therapy solutions, while Varian Medical Systems offers advanced radiotherapy platforms and oncology software used by cancer centers globally.

Siemens Healthineers and Philips Healthcare contribute with high-quality diagnostic imaging systems that support accurate treatment planning. Hitachi Medical Corporation expands access to advanced imaging technologies, and Mevion Medical Systems focuses on compact proton therapy systems, broadening precision radiation treatment options.

Continuous product innovation, software integration, and strategic partnerships remain the key competitive factors shaping the CyberKnife market.

Top Key Players

• Accuray Incorporated
• Advanced Micro Devices
• AiCure
• Arm Limited
• Atomwise Inc.
• Ayasdi AI LLC
• Baidu Inc.
• Brainlab AG
• Elekta AB
• Hitachi Medical Corporation
• Mevion Medical Systems
• Philips Healthcare
• Shimadzu Corporation
• Siemens Healthcare
• Varian Medical Systems
• ViewRay Inc.

Recent Developments

• In October 2025, Accuray Incorporated announced that 5D Clinics and Icon Group treated the first patients in Melbourne, Australia, using the CyberKnife S7® System. The milestone marks the introduction of robotic stereotactic body radiation therapy (SBRT) at the center and supports expansion of CyberKnife services across Australia.
• In September 2025, Elekta AB appointed Jakob Just-Bomholt as President and Chief Executive Officer to accelerate the company’s precision radiation therapy strategy and strengthen its global oncology business.
• In June 2025, Brainlab AG announced the spin-off of Snke Holding SE, creating a dedicated digital health company that includes Snke OS, Mint Medical, VisionTree, and Level Ex. The move strengthens Brainlab’s focus on image-guided surgery and radiation oncology technologies.

Report Scope